Potential role of coenzyme  Q 10 in facilitating recovery from statin‐induced rhabdomyolysis | Zendy

Wang L. W. | Zendy; Jabbour A. | Zendy; Hayward C. S. | Zendy; Furlong T. J. | Zendy; Girgis L. | Zendy; Macdonald P. S. | Zendy; Keogh A. M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Potential role of coenzyme Q 10 in facilitating recovery from statin‐induced rhabdomyolysis

Author(s) -

Wang L. W.,

Jabbour A.,

Hayward C. S.,

Furlong T. J.,

Girgis L.,

Macdonald P. S.,

Keogh A. M.

Publication year - 2015

Publication title -

internal medicine journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.596

H-Index - 70

eISSN - 1445-5994

pISSN - 1444-0903

DOI - 10.1111/imj.12712

Subject(s) - rhabdomyolysis , statin , medicine , coenzyme a , pharmacology , biochemistry , enzyme , chemistry , reductase

Rhabdomyolysis is a rare, but serious complication of statin therapy, and represents the most severe end of the spectrum of statin‐induced myotoxicity. We report a case where coenzyme Q 10 facilitated recovery from statin‐induced rhabdomyolysis and acute renal failure, which had initially persisted despite statin cessation and haemodialysis. This observation is biologically plausible due to the recognised importance of coenzyme Q 10 in mitochondrial bioenergetics within myocytes, and the fact that statins inhibit farnesyl pyrophosphate production, a biochemical step crucial for coenzyme Q 10 synthesis. Coenzyme Q 10 is generally well tolerated, and may potentially benefit patients with statin‐induced rhabdomyolysis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research